Acquisition of Nora Pharma Inc. (Details Narrative) |
12 Months Ended | |||
|---|---|---|---|---|
|
Oct. 20, 2022
USD ($)
shares
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2022
USD ($)
|
Oct. 20, 2022
CAD ($)
|
|
| Business Acquisition [Line Items] | ||||
| Payments to acquire shares | $ (0) | $ 14,346,637 | ||
| Stock issued for acquisition, value | 4,514,000 | |||
| Earnout payable | 2,547,831 | $ 3,632,000 | ||
| Nora Pharma [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Purchase price of shares | $ 18,860,637 | |||
| Payments to acquire shares | $ 14,346,637 | |||
| Stock issued for acquisition | shares | 1,850 | |||
| Stock issued for acquisition, value | $ 4,514,000 | |||
| Nora Pharma [Member] | Malek Chamoun [Member] | ||||
| Business Acquisition [Line Items] | ||||
| Earnout payable | $ 3,632,000 | 2,547,831 | $ 5,000,000 | |
| Payment of earnout liability | $ 1,084,169 | |||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|